When was UDX founded?

UDX was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is UDX located?

UDX is headquartered in Seville, Spain.

How many employees does UDX have?

As of Jul 31, 2026, the latest employee count at UDX is 132.

Is UDX a funded company?

UDX is a funded company, having raised a total of $105M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 2013.

When was the latest funding round of UDX?

UDX's latest funding was a $***** Series C round on Jan 22, 2026, with participation from 1 investor.

Where does UDX rank among its competitors?

UDX ranks 3rd amongst 127 active competitors, of which 44 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of UDX?

UDX's top competitors include Exact Sciences, GRAIL and Volition. Among them, GRAIL secured the most recent funding round in June, 2026.

UDX - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of non-invasive blood-based diagnostics for cancer. The company is developing a screening test that uses metabolomics to analyze patient blood samples and detect early signs of disease. It has developed tests for the early detection of colorectal cancer, lung cancer, and breast cancer.

Website: www.universaldx.com/
Social
Email ID: *****@universaldx.com
Phone Number: +34 **********

Key Metrics

Founded Year

2012

Location

Seville, Spain

Stage

Series C

Total Funding

$105M in 7 rounds

Latest Funding Round

Series C, Jan 22, 2026, $*****

Investors

Olympus & 7 more

Ranked

3^rd among 127 active competitors

Employee Count

132 as on Jul 31, 2026

Similar Companies

Exact Sciences & 180 more

View UDX's full profile

UDX has raised a total funding of $105M over 7 rounds. Its first funding round was on Jun 2013. Its latest funding round was a Series C round on Jan 22, 2026 for $*****. 1 investor participated in its latest round. UDX has 8 institutional investors.

Here is the list of recent funding rounds of UDX:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 22, 2026	2601292	Series C	1521383	3176720	5076897	8668182
Feb 27, 2025	6058136	Venture Debt	8923214	6174397	8464597	European Investment Bank
Aug 16, 2024	3597541	Series B	4091274	2354177	Quest Diagnostics & 1 more	6345229

Access funding benchmarks and valuations. Sign up today!

View details of UDX's funding rounds and investors

The founders of UDX is Marko Bitenc.

Here are the details of UDX's key team members:

Marko Bitenc: Co-Founder of UDX and founder of 1 other company.
Contact Info: 2 email addresses

View details of UDX's Founder profiles and Board Members

UDX's employee count trend

UDX has 132 employees as of Jul 26. Here is UDX's employee count trend over the years:

Uncover UDX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of UDX include Exact Sciences, GRAIL and Volition. Here is the list of Top 10 competitors of UDX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
2nd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Google Ventures & 52 others	71/100
3rd	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, European Investment Bank ... & 6 others	67/100
4th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
5th	Biovica 2009, Uppsala (Sweden), Public	Drug response monitoring assay	$4.27M	EIC Fund, Europa	55/100
6th	Sherlock 2019, Watertown (United States), Acquired	Provider of a diagnostic platform for DNA and RNA detection	$111M	Baidu Ventures, Novalis LifeSciences & 12 others	55/100
7th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
8th	Tethis 2004, Milan (Italy), Series A	Provider of automated solutions for in liquid biopsy	$15.3M	sanpaolope.com, Indaco Venture Partners & 5 others	54/100
9th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
10th	Predilife 2004, Villejuif (France), Public	Provider of personalized breast screening	-	-	52/100